1504:
452:
429:
326:
351:
3825:
3795:
3780:
3855:
3870:
3810:
3765:
3840:
703:
458:
357:
1489:
5180:
31:
2966:
Hashimoto S, Iwamatsu A, Ishiai M, Okawa K, Yamadori T, Matsushita M, et al. (October 1999). "Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling".
57:
3343:
Matsushita M, Yamadori T, Kato S, Takemoto Y, Inazawa J, Baba Y, et al. (April 1998). "Identification and characterization of a novel SH3-domain binding protein, Sab, which preferentially associates with Bruton's tyrosine kinase (BtK)".
2690:
for "A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to
Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Patients With Primary Progressive Multiple Sclerosis" at
2568:
for "A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active
Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With RMS to Evaluate Efficacy and Safety " at
2709:
for "A Study to
Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus - Full Text View - ClinicalTrials.gov" at
2753:
for "ONO-4059 Phase I Dose-escalation Study to
Investigate the Safety and Tolerability of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma and/or Chronic Lymphocytic Leukaemi" at
1503:
2767:
2628:
for "A Phase 2 Clinical Trial of
Tolebrutinib, a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis" at
3824:
2365:
2255:
3794:
2296:
2284:
2383:
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. (March 2021). "Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study".
2256:"FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage"
3300:
Johannes FJ, Hausser A, Storz P, TruckenmĂĽller L, Link G, Kawakami T, et al. (November 1999). "Bruton's tyrosine kinase (Btk) associates with protein kinase C mu".
3779:
465:
364:
2798:
for "Escalating Dose Study in
Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia" at
3854:
4325:
3869:
3809:
2879:
Nixon JC, Rajaiya JB, Ayers N, Evetts S, Webb CF (March 2004). "The transcription factor, Bright, is not expressed in all human B lymphocyte subpopulations".
4749:
3910:
3764:
1530:
1569:(Bruton's agammaglobulinemia); sometimes abbreviated to XLA and selective IgM deficiency. Patients with XLA have normal pre-B cell populations in their
1156:
287:
2771:
1137:
4622:
1511:
BTK plays a crucial role in B cell development as it is required for transmitting signals from the pre-B cell receptor that forms after successful
4048:
3839:
4363:
5205:
4005:
3744:
3631:
Hendriks RW, Kersseboom R (February 2006). "Involvement of SLP-65 and Btk in tumor suppression and malignant transformation of pre-B cells".
1928:
5200:
4033:
2006:
1910:
4401:
4392:
4092:
4087:
4082:
4077:
1372:
451:
4286:
4277:
1379:
4899:
4068:
3683:
1626:(Velexbru), approved in March 2020, in Japan, for the treatment of recurrent or refractory primary central nervous system lymphoma.
428:
3971:
2812:
2168:
Patient and Family
Handbook for The Primary Immune Diseases. Third Edition. 2001. Published by the Immune Deficiency Foundation.
1897:
1876:
1616:(Brukinsa) for mantle cell lymphoma, chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL). It can be taken
3903:
5055:
2285:
BeiGene
Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317. June 2016
2114:"Hypomorphic Mutations in the BCR Signalosome Lead to Selective Immunoglobulin M Deficiency and Impaired B-cell Homeostasis"
1893:
350:
325:
54:
4116:
2455:"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies"
1701:
5170:
3689:
2180:"Refinement of evolutionary medicine predictions based on clinical evidence for the manifestations of Mendelian diseases"
1872:
4547:
4479:
4470:
2369:
2300:
2261:
2240:
1643:
1607:
267:
4853:
4844:
4780:
4608:
1797:
1566:
4291:
1647:
1512:
1470:
464:
363:
5040:
5210:
5156:
5143:
5130:
5117:
5104:
5091:
5078:
3896:
3737:
5050:
457:
356:
5004:
4947:
3941:
3927:
3676:
1754:
1562:
1201:
275:
1581:
of the BTK gene have been identified. Of these, at least 212 are considered to be disease-causing mutations.
4952:
4665:
4656:
1182:
2235:
3954:
2642:
1750:
2504:
Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, et al. (June 2019).
4973:
4892:
4617:
4301:
3667:
3261:"Engagement of the human pre-B cell receptor generates a lipid raft-dependent calcium signaling complex"
1740:
1546:
1482:
5045:
3472:
Uckun FM (September 1998). "Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis".
3153:"Regulation of nuclear localization and transcriptional activity of TFII-I by Bruton's tyrosine kinase"
1700:
Fenebrutinib (GDC-0853) for rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and
3672:
3381:"Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein"
1762:
1758:
3730:
3392:
3213:
3064:
2191:
1736:
1716:
1639:
1603:
1542:
339:
254:
5009:
4315:
3695:
3561:"Branches of the B cell antigen receptor pathway are directed by protein conduits Bam32 and Carma1"
2112:
Geier CB, Sauerwein KM, Leiss-Piller A, Zmek I, Fischer MB, Eibl MM, et al. (18 August 2018).
1732:
1334:
1330:
1279:
1271:
3833:: PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT E41K IN COMPLEX WITH INS(1,3,4,5)P4
2366:"FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma"
1683:
1553:(DAG), which then go on to modulate the activity of downstream proteins during B-cell signalling.
1495:
Part of the TH domain is folded against the PH domain while the rest is intrinsically disordered.
4942:
4699:
4689:
4680:
4508:
4499:
3619:
3526:
3325:
2992:
2799:
2755:
2711:
2692:
2629:
2570:
2551:
2408:
2347:
1722:
1665:
1661:
1469:
BTK contains five different protein interaction domains. These domains include an amino terminal
299:
3888:
1746:
1355:
1326:
1300:
1275:
3379:
Yamadori T, Baba Y, Matsushita M, Hashimoto S, Kurosaki M, Kurosaki T, et al. (May 1999).
2550:
for "A Study of
Efficacy and Safety of M2951 in Subjects With Relapsing Multiple Sclerosis" at
4733:
3702:
3648:
3611:
3582:
3547:
3518:
3489:
3460:
3420:
3361:
3317:
3282:
3241:
3182:
3133:
3092:
3033:
2984:
2980:
2948:
2896:
2861:
2832:"Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia"
2605:
2527:
2486:
2400:
2339:
2217:
2145:
2094:
2045:
2002:
1979:
1840:
1694:
247:
47:
4988:
4983:
4957:
4885:
4010:
3996:
3803:: PH DOMAIN FROM BRUTON'S TYROSINE KINASE IN COMPLEX WITH INOSITOL 1,3,4,5-TETRAKISPHOSPHATE
3640:
3603:
3572:
3510:
3481:
3452:
3410:
3400:
3353:
3309:
3272:
3231:
3221:
3172:
3164:
3123:
3082:
3072:
3023:
3010:
Vargas L, Nore BF, Berglof A, Heinonen JE, Mattsson PT, Smith CI, et al. (March 2002).
2976:
2938:
2930:
2888:
2851:
2843:
2595:
2517:
2476:
2466:
2435:
2392:
2331:
2207:
2199:
2135:
2125:
2084:
2076:
2035:
1969:
1959:
544:
475:
419:
374:
4257:
2165:
5035:
5019:
4932:
4598:
4267:
4252:
4242:
4237:
4217:
4212:
4207:
4202:
4197:
4188:
3923:
3202:"BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement"
2297:"FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma"
1781:
1534:
1447:
519:
3053:"Identification of the binding site for Gqalpha on its effector Bruton's tyrosine kinase"
2919:"Cbl-b positively regulates Btk-mediated activation of phospholipase C-gamma2 in B cells"
1573:
but these cells fail to mature and enter the circulation. The Btk gene is located on the
295:
3396:
3217:
3068:
2195:
702:
5184:
5073:
5014:
4728:
4723:
4718:
4102:
3919:
3151:
Novina CD, Kumar S, Bajpai U, Cheriyath V, Zhang K, Pillai S, et al. (July 1999).
2943:
2918:
2856:
2831:
2481:
2454:
2212:
2179:
2140:
2113:
2089:
2064:
1974:
1947:
1550:
3577:
3560:
3485:
3313:
3277:
3260:
2723:
2660:
2396:
1071:
1066:
1061:
1056:
1051:
1046:
1041:
1036:
1031:
1026:
1021:
1016:
1011:
1006:
1001:
996:
991:
986:
981:
976:
971:
966:
961:
956:
951:
946:
941:
936:
931:
926:
921:
916:
911:
906:
901:
896:
891:
886:
881:
865:
860:
855:
850:
845:
840:
835:
830:
825:
820:
804:
799:
794:
789:
784:
779:
774:
769:
764:
759:
754:
749:
744:
5194:
4978:
4937:
4164:
4025:
3711:
3594:
Carpenter CL (April 2004). "Btk-dependent regulation of phosphoinositide synthesis".
3530:
3456:
3443:
Ochs HD, Aruffo A (December 1993). "Advances in X-linked immunodeficiency diseases".
3415:
3380:
3236:
3201:
3177:
3152:
3112:"Mechanism of Bruton's tyrosine kinase-mediated recruitment and regulation of TFII-I"
3087:
3052:
2412:
2351:
1810:
1635:
1629:
1599:
731:
3623:
3329:
2996:
2830:
Rice WG, Howell SB, Zhang H, Rastgoo N, Local A, Kurtz SE, et al. (July 2022).
4927:
4709:
4420:
4411:
4155:
1785:
1712:
1677:
1671:
1632:(Jaypirca), a reversible (non-covalent) inhibitor of BTK, for mantle cell lymphoma.
1623:
1613:
1574:
537:
316:
2917:
Yasuda T, Tezuka T, Maeda A, Inazu T, Yamanashi Y, Gu H, et al. (July 2002).
2892:
2847:
2794:
2749:
2705:
2686:
2624:
2564:
2546:
279:
303:
5151:
5086:
4922:
2080:
1933:
National Center for
Biotechnology Information, U.S. National Library of Medicine
1915:
National Center for Biotechnology Information, U.S. National Library of Medicine
1570:
1473:(PH) domain, a proline-rich TEC homology (TH) domain, SRC homology (SH) domains
5179:
3644:
3385:
Proceedings of the National Academy of Sciences of the United States of America
3206:
Proceedings of the National Academy of Sciences of the United States of America
3057:
Proceedings of the National Academy of Sciences of the United States of America
2600:
2583:
2471:
2439:
2335:
2203:
1488:
620:
4834:
4829:
4819:
4814:
4805:
4754:
4670:
4560:
3514:
1964:
1816:
1478:
1474:
436:
333:
283:
3077:
2130:
5125:
5099:
3788:: SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, MINIMIZED AVERAGE STRUCTURE
3405:
3012:"Functional interaction of caveolin-1 with Bruton's tyrosine kinase and Bmx"
1593:
1516:
1101:
680:
558:
503:
490:
402:
389:
291:
3652:
3615:
3586:
3551:
3522:
3424:
3357:
3321:
3286:
3186:
3137:
3128:
3111:
3037:
3028:
3011:
2988:
2952:
2900:
2865:
2609:
2531:
2490:
2404:
2343:
2221:
2149:
2098:
2065:"Conformational switches that control the TEC kinase - PLCÎł signaling axis"
2049:
1983:
3863:: NMR STUDY OF THE SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, 20 STRUCTURES
3493:
3464:
3365:
3245:
3226:
3168:
3096:
2522:
2505:
1419:
1414:
4569:
3976:
3668:
GeneReviews/NCBI/NIH/UW entry on X-Linked or Brunton's Agammaglobulinemia
3538:
Etzioni A (April 2002). "Novel aspects of hypogammaglobulinemic states".
2934:
2506:"Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis"
1617:
1578:
1403:
1246:
1227:
3716:
3706:
3607:
1728:
1213:
1168:
258:, AGMX1, AT, ATK, BPK, IMD1, PSCTK1, XLA, Bruton tyrosine kinase, IGHD3
224:
220:
216:
212:
208:
204:
200:
196:
192:
188:
184:
180:
176:
172:
168:
164:
160:
156:
152:
148:
144:
140:
136:
132:
128:
124:
120:
116:
112:
108:
104:
100:
96:
92:
88:
84:
80:
76:
5138:
4908:
4858:
4121:
4057:
4052:
3259:
Guo B, Kato RM, Garcia-Lloret M, Wahl MI, Rawlings DJ (August 2000).
2040:
2023:
1846:
1805:
1765:). The inhibitor targets multiple kinase pathways, including BTK and
1458:
1387:
1123:
2768:"Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL. March 2016"
30:
3878:: Solution Structures of the SH2 domain of Bruton's Tyrosine Kinase
3818:: PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT R28C
5112:
4646:
4524:
4489:
4484:
4460:
4262:
4247:
4232:
4227:
4222:
4174:
4169:
4145:
4140:
4131:
4043:
4038:
4015:
3986:
3981:
1834:
1828:
1766:
1523:
2813:"Lilly inks a $ 690M deal to get its hands on an autoimmune drug"
2236:"FDA approves new treatment for adults with mantle cell lymphoma"
1086:
1082:
4764:
4694:
4641:
4632:
4593:
4584:
4574:
4455:
4446:
4436:
4382:
4373:
4358:
4349:
4339:
4334:
4310:
4111:
3963:
3501:
Tsubata T, Wienands J (2001). "B cell signaling. Introduction".
2024:"Signalling through the high-affinity IgE receptor Fc epsilonRI"
1822:
1650:(CLL/SLL), who have received at least one treatment in the past.
1454:
882:
transmembrane receptor protein tyrosine kinase signaling pathway
271:
4881:
4545:
3939:
3892:
3726:
3110:
Sacristán C, Tussié-Luna MI, Logan SM, Roy AL (February 2004).
4795:
4790:
4785:
4759:
3773:: SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, 42 STRUCTURES
3722:
1948:"Role of Bruton's tyrosine kinase in B cells and malignancies"
1520:
907:
positive regulation of NF-kappaB transcription factor activity
711:
3701:
Overview of all the structural information available in the
1596:(Imbruvica), a selective Bruton's tyrosine kinase inhibitor.
1502:
1487:
4877:
841:
extrinsic component of cytoplasmic side of plasma membrane
1719:
and/or CLL. Renamed GS-4059 and now in trial NCT02457598.
527:
2322:
Dhillon S (June 2020). "Tirabrutinib: First Approval".
1946:
Pal Singh S, Dammeijer F, Hendriks RW (February 2018).
1654:
Various drugs that inhibit BTK are in clinical trials:
3848:: Crystal structure of Bruton's tyrosine kinase domain
790:
non-membrane spanning protein tyrosine kinase activity
5168:
692:
2001:(7th ed.). New York: W.H. Freeman. p. 93.
962:
MyD88-dependent toll-like receptor signaling pathway
5064:
5028:
4997:
4966:
4915:
4843:
4804:
4773:
4742:
4708:
4679:
4655:
4631:
4607:
4583:
4559:
4517:
4498:
4469:
4445:
4429:
4410:
4391:
4372:
4348:
4324:
4300:
4276:
4187:
4154:
4130:
4101:
4067:
4024:
3995:
3962:
3953:
3346:
Biochemical and Biophysical Research Communications
2426:Dhillon S (2021). "Orelabrutinib: First Approval".
1602:(Calquence), approved in October 2017 for relapsed
1348:
1319:
1293:
1264:
2453:Alu A, Lei H, Han X, Wei Y, Wei X (October 2022).
2063:Lowe J, Joseph RE, Andreotti AH (1 January 2022).
1889:
1887:
1885:
1868:
1866:
1864:
1533:(PIP3). PIP3 binding induces Btk to phosphorylate
2584:"BTK blockers make headway in multiple sclerosis"
474:
373:
1997:Owen JA, Punt J, Stranford SA, Jones PP (2013).
1561:Mutations in the BTK gene are implicated in the
1027:positive regulation of type III hypersensitivity
785:phosphatidylinositol-3,4,5-trisphosphate binding
2912:
2910:
1507:Involvement of BTK in B cell receptor signaling
1894:GRCm38: Ensembl release 89: ENSMUSG00000031264
1749:(CG-806), for CLL, SLL, non-Hodgkin lymphoma,
1047:positive regulation of type I hypersensitivity
1042:cellular response to molecule of fungal origin
16:Kinase that plays a role in B cell development
4893:
3904:
3738:
917:positive regulation of B cell differentiation
8:
1072:G protein-coupled receptor signaling pathway
1037:cellular response to reactive oxygen species
1873:GRCh38: Ensembl release 89: ENSG00000010671
1796:Bruton's tyrosine kinase has been shown to
1057:negative regulation of B cell proliferation
932:regulation of cell population proliferation
4900:
4886:
4878:
4556:
4542:
3959:
3950:
3936:
3911:
3897:
3889:
3745:
3731:
3723:
1610:(CLL) and Small lymphocytic lymphoma (SLL)
1531:phosphatidylinositol (3,4,5)-trisphosphate
1097:
987:regulation of transcription, DNA-templated
957:negative regulation of cytokine production
727:
515:
414:
311:
65:
3675:at the U.S. National Library of Medicine
3576:
3414:
3404:
3276:
3235:
3225:
3176:
3127:
3086:
3076:
3027:
2981:10.1182/blood.V94.7.2357.419k40_2357_2364
2942:
2855:
2599:
2521:
2480:
2470:
2211:
2178:Ĺ imÄŤĂková D, Heneberg P (December 2019).
2139:
2129:
2088:
2039:
1973:
1963:
639:fetal liver hematopoietic progenitor cell
1784:was discovered in 1993 and is named for
1485:with tyrosine phosphorylation activity.
1002:regulation of B cell cytokine production
5175:
3760:
1860:
1457:in humans. BTK plays a crucial role in
3540:The Israel Medical Association Journal
2161:
2159:
1697:for systemic lupus erythematosus (SLE)
1638:, approved in China for patients with
1007:regulation of B cell apoptotic process
20:
3715:(Tyrosine-protein kinase BTK) at the
2643:"Remibrutinib for Multiple Sclerosis"
1519:activation through the high-affinity
1515:rearrangement. It also has a role in
927:Fc-epsilon receptor signaling pathway
897:peptidyl-tyrosine autophosphorylation
479:
440:
435:
378:
337:
332:
7:
3200:Yang W, Desiderio S (January 1997).
2923:The Journal of Experimental Medicine
2459:Journal of Hematology & Oncology
2022:Turner H, Kinet JP (November 1999).
1529:Btk contains a PH domain that binds
3559:Niiro H, Clark EA (November 2003).
3503:International Reviews of Immunology
3116:The Journal of Biological Chemistry
3016:The Journal of Biological Chemistry
2510:The New England Journal of Medicine
1788:, who first described XLA in 1952.
977:I-kappaB kinase/NF-kappaB signaling
1345:
1316:
1290:
1261:
1237:
1218:
1192:
1173:
1147:
1128:
1062:cellular response to interleukin-7
697:
615:
553:
532:
14:
2266:(Press release). 14 November 2019
1589:Approved drugs that inhibit BTK:
1067:T cell receptor signaling pathway
947:peptidyl-tyrosine phosphorylation
922:B cell receptor signaling pathway
892:intracellular signal transduction
5178:
3868:
3853:
3838:
3823:
3808:
3793:
3778:
3763:
3596:Biochemical Society Transactions
3457:10.1097/00008480-199312000-00008
3051:Ma YC, Huang XY (October 1998).
1686:(RG7845) for multiple sclerosis.
1017:histamine secretion by mast cell
805:protein tyrosine kinase activity
701:
463:
456:
450:
427:
362:
355:
349:
324:
29:
861:perinuclear region of cytoplasm
3157:Molecular and Cellular Biology
1545:, into two second messengers,
1537:, which in turn hydrolyzes PIP
712:More reference expression data
681:More reference expression data
1:
4548:Non-receptor tyrosine kinases
3578:10.1016/S1074-7613(03)00303-0
3486:10.1016/S0006-2952(98)00122-1
3445:Current Opinion in Pediatrics
3314:10.1016/S0014-5793(99)01424-6
3278:10.1016/s1074-7613(00)00024-8
2893:10.1016/j.cellimm.2004.03.004
2848:10.1158/1535-7163.MCT-21-0832
2836:Molecular Cancer Therapeutics
2397:10.1016/S0140-6736(21)00224-5
2069:Journal of Structural Biology
1702:chronic spontaneous urticaria
1022:response to organic substance
448:
347:
5206:Peripheral membrane proteins
3673:Bruton's+tyrosine+kinase
2370:Food and Drug Administration
2301:Food and Drug Administration
2262:Food and Drug Administration
2241:Food and Drug Administration
1644:chronic lymphocytic leukemia
1608:Chronic lymphocytic leukemia
912:transcription, DNA-templated
5201:Genes on human chromosome X
2166:X-Linked Agammaglobulinemia
2081:10.1016/j.yjsbx.2022.100061
1577:(Xq21.3-q22). At least 400
1567:X-linked agammaglobulinemia
1444:tyrosine-protein kinase BTK
1032:protein autophosphorylation
967:apoptotic signaling pathway
5227:
3694:gene details page in the
3645:10.1016/j.smim.2005.10.002
2601:10.1038/s41587-020-00790-7
2472:10.1186/s13045-022-01353-w
2440:10.1007/s40265-021-01482-5
2336:10.1007/s40265-020-01318-8
2204:10.1038/s41598-019-54976-4
1648:small lymphocytic lymphoma
1513:immunoglobulin heavy chain
1052:B cell affinity maturation
972:calcium-mediated signaling
760:signaling receptor binding
5056:Michaelis–Menten kinetics
4555:
4541:
3949:
3942:Receptor tyrosine kinases
3935:
3758:
3515:10.3109/08830180109045584
2811:Garde D (19 March 2015).
2724:"Genentech: Our Pipeline"
2661:"Genentech: Our Pipeline"
2641:Wexler M (21 June 2022).
2582:Dolgin E (January 2021).
1965:10.1186/s12943-018-0779-z
1929:"Mouse PubMed Reference:"
1911:"Human PubMed Reference:"
1755:myelodysplastic syndromes
1680:, for multiple sclerosis.
1674:, for multiple sclerosis.
1418:
1413:
1409:
1402:
1386:
1380:Chr X: 133.44 – 133.48 Mb
1373:Chr X: 101.35 – 101.39 Mb
1367:
1352:
1323:
1312:
1297:
1268:
1257:
1244:
1240:
1225:
1221:
1212:
1199:
1195:
1180:
1176:
1167:
1154:
1150:
1135:
1131:
1122:
1107:
1100:
1096:
1080:
765:identical protein binding
730:
726:
709:
700:
691:
678:
627:
618:
597:epithelium of nasopharynx
565:
556:
526:
518:
514:
497:
484:
447:
426:
417:
413:
396:
383:
346:
323:
314:
310:
265:
262:
252:
245:
240:
73:
68:
51:
46:
41:
37:
28:
23:
4948:Diffusion-limited enzyme
3677:Medical Subject Headings
3474:Biochemical Pharmacology
3078:10.1073/pnas.95.21.12197
2131:10.3389/fimmu.2018.02984
1606:and in October 2019 for
1563:primary immunodeficiency
1432:Bruton's tyrosine kinase
937:adaptive immune response
3955:Growth factor receptors
3406:10.1073/pnas.96.11.6341
2372:(FDA). 27 January 2023.
2118:Frontiers in Immunology
2034:(6760 Suppl): B24–B30.
1751:acute myeloid leukaemia
1735:, under development by
1450:that is encoded by the
952:protein phosphorylation
770:protein kinase activity
605:upper lobe of left lung
3633:Seminars in Immunology
3358:10.1006/bbrc.1998.8420
3129:10.1074/jbc.M303724200
3029:10.1074/jbc.M108537200
2792:Clinical trial number
2747:Clinical trial number
2703:Clinical trial number
2684:Clinical trial number
2622:Clinical trial number
2562:Clinical trial number
2544:Clinical trial number
2303:(FDA). 19 January 2023
1508:
1492:
982:innate immune response
643:mesenteric lymph nodes
5041:Eadie–Hofstee diagram
4974:Allosteric regulation
3227:10.1073/pnas.94.2.604
3169:10.1128/mcb.19.7.5014
2523:10.1056/NEJMoa1901981
1557:Clinical significance
1547:inositol triphosphate
1506:
1491:
1483:protein kinase domain
997:immune system process
667:stroma of bone marrow
5051:Lineweaver–Burk plot
4026:PDGF receptor family
3688:genome location and
2935:10.1084/jem.20020068
2588:Nature Biotechnology
1737:Hanmi Pharmaceutical
1717:non-Hodgkin lymphoma
1640:mantle cell lymphoma
1604:mantle cell lymphoma
1543:phosphatidylinositol
887:mesoderm development
775:transferase activity
481:X E3|X 56.18 cM
442:X chromosome (mouse)
340:X chromosome (human)
69:List of PDB id codes
42:Available structures
4430:ROS receptor family
3964:EGF receptor family
3696:UCSC Genome Browser
3397:1999PNAS...96.6341Y
3218:1997PNAS...94..604Y
3069:1998PNAS...9512197M
3063:(21): 12197–12201.
2881:Cellular Immunology
2196:2019NatSR...918577S
1733:autoimmune diseases
1471:pleckstrin homology
846:cytoplasmic vesicle
5010:Enzyme superfamily
4943:Enzyme promiscuity
3608:10.1042/BST0320326
2800:ClinicalTrials.gov
2756:ClinicalTrials.gov
2712:ClinicalTrials.gov
2693:ClinicalTrials.gov
2630:ClinicalTrials.gov
2571:ClinicalTrials.gov
2552:ClinicalTrials.gov
2391:(10277): 892–901.
2184:Scientific Reports
1725:(AVL-292, CC-292)
1666:multiple sclerosis
1509:
1493:
1202:ENSMUSG00000031264
875:Biological process
814:Cellular component
750:nucleotide binding
738:Molecular function
647:tibiofemoral joint
5166:
5165:
4875:
4874:
4871:
4870:
4867:
4866:
4537:
4536:
4533:
4532:
4183:
4182:
3886:
3885:
3602:(Pt 2): 326–329.
3391:(11): 6341–6346.
3022:(11): 9351–9357.
2516:(25): 2406–2417.
1442:), also known as
1429:
1428:
1425:
1424:
1398:
1397:
1363:
1362:
1342:
1341:
1308:
1307:
1287:
1286:
1253:
1252:
1234:
1233:
1208:
1207:
1189:
1188:
1163:
1162:
1144:
1143:
1092:
1091:
942:apoptotic process
902:B cell activation
866:mast cell granule
745:metal ion binding
722:
721:
718:
717:
687:
686:
674:
673:
612:
611:
581:bone marrow cells
510:
509:
409:
408:
236:
235:
232:
231:
52:Ortholog search:
5218:
5211:Tyrosine kinases
5183:
5182:
5174:
5046:Hanes–Woolf plot
4989:Enzyme activator
4984:Enzyme inhibitor
4958:Enzyme catalysis
4902:
4895:
4888:
4879:
4557:
4543:
3997:Insulin receptor
3960:
3951:
3937:
3924:tyrosine kinases
3913:
3906:
3899:
3890:
3872:
3857:
3842:
3827:
3812:
3797:
3782:
3767:
3747:
3740:
3733:
3724:
3656:
3627:
3590:
3580:
3555:
3534:
3497:
3468:
3429:
3428:
3418:
3408:
3376:
3370:
3369:
3340:
3334:
3333:
3297:
3291:
3290:
3280:
3256:
3250:
3249:
3239:
3229:
3197:
3191:
3190:
3180:
3163:(7): 5014–5024.
3148:
3142:
3141:
3131:
3122:(8): 7147–7158.
3107:
3101:
3100:
3090:
3080:
3048:
3042:
3041:
3031:
3007:
3001:
3000:
2975:(7): 2357–2364.
2963:
2957:
2956:
2946:
2914:
2905:
2904:
2876:
2870:
2869:
2859:
2842:(7): 1125–1135.
2827:
2821:
2820:
2808:
2802:
2790:
2784:
2783:
2781:
2779:
2770:. Archived from
2764:
2758:
2745:
2739:
2738:
2736:
2734:
2720:
2714:
2701:
2695:
2682:
2676:
2675:
2673:
2671:
2657:
2651:
2650:
2638:
2632:
2620:
2614:
2613:
2603:
2579:
2573:
2560:
2554:
2542:
2536:
2535:
2525:
2501:
2495:
2494:
2484:
2474:
2450:
2444:
2443:
2423:
2417:
2416:
2380:
2374:
2373:
2362:
2356:
2355:
2319:
2313:
2312:
2310:
2308:
2293:
2287:
2282:
2276:
2275:
2273:
2271:
2252:
2246:
2245:
2244:. 24 March 2020.
2232:
2226:
2225:
2215:
2175:
2169:
2163:
2154:
2153:
2143:
2133:
2109:
2103:
2102:
2092:
2060:
2054:
2053:
2043:
2041:10.1038/35037021
2019:
2013:
2012:
2008:978-14641-3784-6
1994:
1988:
1987:
1977:
1967:
1952:Molecular Cancer
1943:
1937:
1936:
1925:
1919:
1918:
1907:
1901:
1891:
1880:
1870:
1411:
1410:
1382:
1375:
1358:
1346:
1337:
1317:
1313:RefSeq (protein)
1303:
1291:
1282:
1262:
1238:
1219:
1193:
1174:
1148:
1129:
1098:
728:
714:
705:
698:
683:
659:secondary oocyte
623:
621:Top expressed in
616:
561:
559:Top expressed in
554:
533:
516:
506:
493:
482:
467:
460:
454:
443:
431:
415:
405:
392:
381:
366:
359:
353:
342:
328:
312:
306:
257:
250:
227:
66:
60:
39:
38:
33:
21:
5226:
5225:
5221:
5220:
5219:
5217:
5216:
5215:
5191:
5190:
5189:
5177:
5169:
5167:
5162:
5074:Oxidoreductases
5060:
5036:Enzyme kinetics
5024:
5020:List of enzymes
4993:
4962:
4933:Catalytic triad
4911:
4906:
4876:
4863:
4839:
4800:
4769:
4738:
4704:
4675:
4651:
4627:
4603:
4579:
4551:
4529:
4513:
4494:
4465:
4441:
4425:
4406:
4387:
4368:
4344:
4320:
4296:
4272:
4179:
4150:
4126:
4097:
4063:
4020:
3991:
3945:
3931:
3920:Protein kinases
3917:
3887:
3882:
3879:
3873:
3864:
3858:
3849:
3843:
3834:
3828:
3819:
3813:
3804:
3798:
3789:
3783:
3774:
3768:
3754:
3751:
3664:
3659:
3630:
3593:
3558:
3537:
3500:
3471:
3442:
3438:
3436:Further reading
3433:
3432:
3378:
3377:
3373:
3342:
3341:
3337:
3299:
3298:
3294:
3258:
3257:
3253:
3199:
3198:
3194:
3150:
3149:
3145:
3109:
3108:
3104:
3050:
3049:
3045:
3009:
3008:
3004:
2965:
2964:
2960:
2916:
2915:
2908:
2878:
2877:
2873:
2829:
2828:
2824:
2810:
2809:
2805:
2791:
2787:
2777:
2775:
2774:on 5 April 2016
2766:
2765:
2761:
2746:
2742:
2732:
2730:
2722:
2721:
2717:
2702:
2698:
2683:
2679:
2669:
2667:
2659:
2658:
2654:
2640:
2639:
2635:
2621:
2617:
2581:
2580:
2576:
2561:
2557:
2543:
2539:
2503:
2502:
2498:
2452:
2451:
2447:
2425:
2424:
2420:
2382:
2381:
2377:
2364:
2363:
2359:
2321:
2320:
2316:
2306:
2304:
2295:
2294:
2290:
2283:
2279:
2269:
2267:
2254:
2253:
2249:
2234:
2233:
2229:
2177:
2176:
2172:
2164:
2157:
2111:
2110:
2106:
2062:
2061:
2057:
2021:
2020:
2016:
2009:
1999:Kuby Immunology
1996:
1995:
1991:
1945:
1944:
1940:
1927:
1926:
1922:
1909:
1908:
1904:
1892:
1883:
1871:
1862:
1857:
1852:
1794:
1782:tyrosine kinase
1778:
1587:
1559:
1540:
1535:phospholipase C
1501:
1481:, as well as a
1467:
1448:tyrosine kinase
1420:View/Edit Mouse
1415:View/Edit Human
1378:
1371:
1368:Location (UCSC)
1354:
1333:
1329:
1325:
1299:
1278:
1274:
1270:
1183:ENSG00000010671
1076:
1012:phosphorylation
992:cell maturation
870:
856:plasma membrane
809:
800:protein binding
780:kinase activity
710:
679:
670:
665:
661:
657:
653:
649:
645:
641:
637:
633:
619:
608:
603:
599:
595:
591:
587:
583:
579:
575:
571:
557:
501:
488:
480:
470:
469:
468:
461:
441:
418:Gene location (
400:
387:
379:
369:
368:
367:
360:
338:
315:Gene location (
304:BTK - orthologs
266:
253:
246:
75:
53:
17:
12:
11:
5:
5224:
5222:
5214:
5213:
5208:
5203:
5193:
5192:
5188:
5187:
5164:
5163:
5161:
5160:
5147:
5134:
5121:
5108:
5095:
5082:
5068:
5066:
5062:
5061:
5059:
5058:
5053:
5048:
5043:
5038:
5032:
5030:
5026:
5025:
5023:
5022:
5017:
5012:
5007:
5001:
4999:
4998:Classification
4995:
4994:
4992:
4991:
4986:
4981:
4976:
4970:
4968:
4964:
4963:
4961:
4960:
4955:
4950:
4945:
4940:
4935:
4930:
4925:
4919:
4917:
4913:
4912:
4907:
4905:
4904:
4897:
4890:
4882:
4873:
4872:
4869:
4868:
4865:
4864:
4862:
4861:
4856:
4850:
4848:
4841:
4840:
4838:
4837:
4832:
4827:
4822:
4817:
4811:
4809:
4802:
4801:
4799:
4798:
4793:
4788:
4783:
4777:
4775:
4771:
4770:
4768:
4767:
4762:
4757:
4752:
4746:
4744:
4740:
4739:
4737:
4736:
4731:
4726:
4721:
4715:
4713:
4706:
4705:
4703:
4702:
4697:
4692:
4686:
4684:
4677:
4676:
4674:
4673:
4668:
4662:
4660:
4653:
4652:
4650:
4649:
4644:
4638:
4636:
4629:
4628:
4626:
4625:
4620:
4614:
4612:
4605:
4604:
4602:
4601:
4596:
4590:
4588:
4581:
4580:
4578:
4577:
4572:
4566:
4564:
4553:
4552:
4546:
4539:
4538:
4535:
4534:
4531:
4530:
4528:
4527:
4521:
4519:
4515:
4514:
4512:
4511:
4505:
4503:
4496:
4495:
4493:
4492:
4487:
4482:
4476:
4474:
4467:
4466:
4464:
4463:
4458:
4452:
4450:
4447:AATYK receptor
4443:
4442:
4440:
4439:
4433:
4431:
4427:
4426:
4424:
4423:
4417:
4415:
4408:
4407:
4405:
4404:
4398:
4396:
4389:
4388:
4386:
4385:
4379:
4377:
4370:
4369:
4367:
4366:
4361:
4355:
4353:
4346:
4345:
4343:
4342:
4337:
4331:
4329:
4322:
4321:
4319:
4318:
4313:
4307:
4305:
4298:
4297:
4295:
4294:
4289:
4283:
4281:
4274:
4273:
4271:
4270:
4265:
4260:
4255:
4250:
4245:
4240:
4235:
4230:
4225:
4220:
4215:
4210:
4205:
4200:
4194:
4192:
4185:
4184:
4181:
4180:
4178:
4177:
4172:
4167:
4161:
4159:
4152:
4151:
4149:
4148:
4143:
4137:
4135:
4128:
4127:
4125:
4124:
4119:
4114:
4108:
4106:
4103:VEGF receptors
4099:
4098:
4096:
4095:
4090:
4085:
4080:
4074:
4072:
4065:
4064:
4062:
4061:
4055:
4046:
4041:
4036:
4030:
4028:
4022:
4021:
4019:
4018:
4013:
4008:
4002:
4000:
3993:
3992:
3990:
3989:
3984:
3979:
3974:
3968:
3966:
3957:
3947:
3946:
3940:
3933:
3932:
3918:
3916:
3915:
3908:
3901:
3893:
3884:
3883:
3881:
3880:
3874:
3867:
3865:
3859:
3852:
3850:
3844:
3837:
3835:
3829:
3822:
3820:
3814:
3807:
3805:
3799:
3792:
3790:
3784:
3777:
3775:
3769:
3762:
3759:
3756:
3755:
3752:
3750:
3749:
3742:
3735:
3727:
3721:
3720:
3699:
3680:
3670:
3663:
3662:External links
3660:
3658:
3657:
3628:
3591:
3571:(5): 637–640.
3556:
3546:(4): 294–297.
3535:
3509:(6): 675–678.
3498:
3480:(6): 683–691.
3469:
3451:(6): 684–691.
3439:
3437:
3434:
3431:
3430:
3371:
3352:(2): 337–343.
3335:
3308:(1–2): 68–72.
3292:
3271:(2): 243–253.
3251:
3212:(2): 604–609.
3192:
3143:
3102:
3043:
3002:
2958:
2906:
2871:
2822:
2803:
2785:
2759:
2740:
2715:
2696:
2677:
2652:
2633:
2615:
2574:
2555:
2537:
2496:
2445:
2434:(4): 503–507.
2418:
2375:
2357:
2330:(8): 835–840.
2314:
2288:
2277:
2247:
2227:
2170:
2155:
2104:
2055:
2014:
2007:
1989:
1938:
1920:
1902:
1881:
1859:
1858:
1856:
1853:
1851:
1850:
1844:
1838:
1832:
1826:
1820:
1814:
1808:
1802:
1793:
1790:
1777:
1774:
1773:
1772:
1771:
1770:
1744:
1726:
1720:
1707:
1706:
1705:
1698:
1689:
1688:
1687:
1681:
1675:
1669:
1652:
1651:
1633:
1627:
1621:
1611:
1597:
1586:
1585:BTK inhibitors
1583:
1558:
1555:
1551:diacylglycerol
1538:
1500:
1497:
1466:
1463:
1427:
1426:
1423:
1422:
1417:
1407:
1406:
1400:
1399:
1396:
1395:
1393:
1391:
1384:
1383:
1376:
1369:
1365:
1364:
1361:
1360:
1350:
1349:
1343:
1340:
1339:
1321:
1320:
1314:
1310:
1309:
1306:
1305:
1295:
1294:
1288:
1285:
1284:
1266:
1265:
1259:
1255:
1254:
1251:
1250:
1242:
1241:
1235:
1232:
1231:
1223:
1222:
1216:
1210:
1209:
1206:
1205:
1197:
1196:
1190:
1187:
1186:
1178:
1177:
1171:
1165:
1164:
1161:
1160:
1152:
1151:
1145:
1142:
1141:
1133:
1132:
1126:
1120:
1119:
1114:
1109:
1105:
1104:
1094:
1093:
1090:
1089:
1078:
1077:
1075:
1074:
1069:
1064:
1059:
1054:
1049:
1044:
1039:
1034:
1029:
1024:
1019:
1014:
1009:
1004:
999:
994:
989:
984:
979:
974:
969:
964:
959:
954:
949:
944:
939:
934:
929:
924:
919:
914:
909:
904:
899:
894:
889:
884:
878:
876:
872:
871:
869:
868:
863:
858:
853:
848:
843:
838:
833:
828:
823:
817:
815:
811:
810:
808:
807:
802:
797:
792:
787:
782:
777:
772:
767:
762:
757:
752:
747:
741:
739:
735:
734:
724:
723:
720:
719:
716:
715:
707:
706:
695:
689:
688:
685:
684:
676:
675:
672:
671:
669:
668:
664:
660:
656:
652:
648:
644:
640:
636:
632:
628:
625:
624:
613:
610:
609:
607:
606:
602:
598:
594:
590:
586:
582:
578:
574:
570:
566:
563:
562:
550:
549:
541:
530:
524:
523:
520:RNA expression
512:
511:
508:
507:
499:
495:
494:
486:
483:
478:
472:
471:
462:
455:
449:
445:
444:
439:
433:
432:
424:
423:
411:
410:
407:
406:
398:
394:
393:
385:
382:
377:
371:
370:
361:
354:
348:
344:
343:
336:
330:
329:
321:
320:
308:
307:
264:
260:
259:
251:
243:
242:
238:
237:
234:
233:
230:
229:
71:
70:
62:
61:
50:
44:
43:
35:
34:
26:
25:
15:
13:
10:
9:
6:
4:
3:
2:
5223:
5212:
5209:
5207:
5204:
5202:
5199:
5198:
5196:
5186:
5181:
5176:
5172:
5158:
5154:
5153:
5148:
5145:
5141:
5140:
5135:
5132:
5128:
5127:
5122:
5119:
5115:
5114:
5109:
5106:
5102:
5101:
5096:
5093:
5089:
5088:
5083:
5080:
5076:
5075:
5070:
5069:
5067:
5063:
5057:
5054:
5052:
5049:
5047:
5044:
5042:
5039:
5037:
5034:
5033:
5031:
5027:
5021:
5018:
5016:
5015:Enzyme family
5013:
5011:
5008:
5006:
5003:
5002:
5000:
4996:
4990:
4987:
4985:
4982:
4980:
4979:Cooperativity
4977:
4975:
4972:
4971:
4969:
4965:
4959:
4956:
4954:
4951:
4949:
4946:
4944:
4941:
4939:
4938:Oxyanion hole
4936:
4934:
4931:
4929:
4926:
4924:
4921:
4920:
4918:
4914:
4910:
4903:
4898:
4896:
4891:
4889:
4884:
4883:
4880:
4860:
4857:
4855:
4852:
4851:
4849:
4846:
4842:
4836:
4833:
4831:
4828:
4826:
4823:
4821:
4818:
4816:
4813:
4812:
4810:
4807:
4803:
4797:
4794:
4792:
4789:
4787:
4784:
4782:
4779:
4778:
4776:
4772:
4766:
4763:
4761:
4758:
4756:
4753:
4751:
4748:
4747:
4745:
4741:
4735:
4732:
4730:
4727:
4725:
4722:
4720:
4717:
4716:
4714:
4711:
4707:
4701:
4698:
4696:
4693:
4691:
4688:
4687:
4685:
4682:
4678:
4672:
4669:
4667:
4664:
4663:
4661:
4658:
4654:
4648:
4645:
4643:
4640:
4639:
4637:
4634:
4630:
4624:
4621:
4619:
4616:
4615:
4613:
4610:
4606:
4600:
4597:
4595:
4592:
4591:
4589:
4586:
4582:
4576:
4573:
4571:
4568:
4567:
4565:
4562:
4558:
4554:
4550:(EC 2.7.10.2)
4549:
4544:
4540:
4526:
4523:
4522:
4520:
4518:uncategorised
4516:
4510:
4507:
4506:
4504:
4501:
4497:
4491:
4488:
4486:
4483:
4481:
4478:
4477:
4475:
4472:
4468:
4462:
4459:
4457:
4454:
4453:
4451:
4448:
4444:
4438:
4435:
4434:
4432:
4428:
4422:
4419:
4418:
4416:
4413:
4412:MuSK receptor
4409:
4403:
4400:
4399:
4397:
4394:
4390:
4384:
4381:
4380:
4378:
4375:
4374:PTK7 receptor
4371:
4365:
4362:
4360:
4357:
4356:
4354:
4351:
4347:
4341:
4338:
4336:
4333:
4332:
4330:
4327:
4323:
4317:
4314:
4312:
4309:
4308:
4306:
4303:
4299:
4293:
4290:
4288:
4285:
4284:
4282:
4279:
4275:
4269:
4266:
4264:
4261:
4259:
4256:
4254:
4251:
4249:
4246:
4244:
4241:
4239:
4236:
4234:
4231:
4229:
4226:
4224:
4221:
4219:
4216:
4214:
4211:
4209:
4206:
4204:
4201:
4199:
4196:
4195:
4193:
4190:
4186:
4176:
4173:
4171:
4168:
4166:
4163:
4162:
4160:
4157:
4153:
4147:
4144:
4142:
4139:
4138:
4136:
4133:
4129:
4123:
4120:
4118:
4115:
4113:
4110:
4109:
4107:
4104:
4100:
4094:
4091:
4089:
4086:
4084:
4081:
4079:
4076:
4075:
4073:
4070:
4066:
4059:
4056:
4054:
4050:
4047:
4045:
4042:
4040:
4037:
4035:
4032:
4031:
4029:
4027:
4023:
4017:
4014:
4012:
4009:
4007:
4004:
4003:
4001:
3998:
3994:
3988:
3985:
3983:
3980:
3978:
3975:
3973:
3970:
3969:
3967:
3965:
3961:
3958:
3956:
3952:
3948:
3944:(EC 2.7.10.1)
3943:
3938:
3934:
3929:
3925:
3921:
3914:
3909:
3907:
3902:
3900:
3895:
3894:
3891:
3877:
3871:
3866:
3862:
3856:
3851:
3847:
3841:
3836:
3832:
3826:
3821:
3817:
3811:
3806:
3802:
3796:
3791:
3787:
3781:
3776:
3772:
3766:
3761:
3757:
3748:
3743:
3741:
3736:
3734:
3729:
3728:
3725:
3718:
3714:
3713:
3708:
3704:
3700:
3697:
3693:
3692:
3687:
3686:
3681:
3678:
3674:
3671:
3669:
3666:
3665:
3661:
3654:
3650:
3646:
3642:
3638:
3634:
3629:
3625:
3621:
3617:
3613:
3609:
3605:
3601:
3597:
3592:
3588:
3584:
3579:
3574:
3570:
3566:
3562:
3557:
3553:
3549:
3545:
3541:
3536:
3532:
3528:
3524:
3520:
3516:
3512:
3508:
3504:
3499:
3495:
3491:
3487:
3483:
3479:
3475:
3470:
3466:
3462:
3458:
3454:
3450:
3446:
3441:
3440:
3435:
3426:
3422:
3417:
3412:
3407:
3402:
3398:
3394:
3390:
3386:
3382:
3375:
3372:
3367:
3363:
3359:
3355:
3351:
3347:
3339:
3336:
3331:
3327:
3323:
3319:
3315:
3311:
3307:
3303:
3296:
3293:
3288:
3284:
3279:
3274:
3270:
3266:
3262:
3255:
3252:
3247:
3243:
3238:
3233:
3228:
3223:
3219:
3215:
3211:
3207:
3203:
3196:
3193:
3188:
3184:
3179:
3174:
3170:
3166:
3162:
3158:
3154:
3147:
3144:
3139:
3135:
3130:
3125:
3121:
3117:
3113:
3106:
3103:
3098:
3094:
3089:
3084:
3079:
3074:
3070:
3066:
3062:
3058:
3054:
3047:
3044:
3039:
3035:
3030:
3025:
3021:
3017:
3013:
3006:
3003:
2998:
2994:
2990:
2986:
2982:
2978:
2974:
2970:
2962:
2959:
2954:
2950:
2945:
2940:
2936:
2932:
2928:
2924:
2920:
2913:
2911:
2907:
2902:
2898:
2894:
2890:
2886:
2882:
2875:
2872:
2867:
2863:
2858:
2853:
2849:
2845:
2841:
2837:
2833:
2826:
2823:
2818:
2817:FierceBiotech
2814:
2807:
2804:
2801:
2797:
2796:
2789:
2786:
2773:
2769:
2763:
2760:
2757:
2752:
2751:
2744:
2741:
2729:
2725:
2719:
2716:
2713:
2708:
2707:
2700:
2697:
2694:
2689:
2688:
2681:
2678:
2666:
2662:
2656:
2653:
2648:
2644:
2637:
2634:
2631:
2627:
2626:
2619:
2616:
2611:
2607:
2602:
2597:
2593:
2589:
2585:
2578:
2575:
2572:
2567:
2566:
2559:
2556:
2553:
2549:
2548:
2541:
2538:
2533:
2529:
2524:
2519:
2515:
2511:
2507:
2500:
2497:
2492:
2488:
2483:
2478:
2473:
2468:
2464:
2460:
2456:
2449:
2446:
2441:
2437:
2433:
2429:
2422:
2419:
2414:
2410:
2406:
2402:
2398:
2394:
2390:
2386:
2379:
2376:
2371:
2367:
2361:
2358:
2353:
2349:
2345:
2341:
2337:
2333:
2329:
2325:
2318:
2315:
2302:
2298:
2292:
2289:
2286:
2281:
2278:
2265:
2263:
2257:
2251:
2248:
2243:
2242:
2237:
2231:
2228:
2223:
2219:
2214:
2209:
2205:
2201:
2197:
2193:
2189:
2185:
2181:
2174:
2171:
2167:
2162:
2160:
2156:
2151:
2147:
2142:
2137:
2132:
2127:
2123:
2119:
2115:
2108:
2105:
2100:
2096:
2091:
2086:
2082:
2078:
2074:
2070:
2066:
2059:
2056:
2051:
2047:
2042:
2037:
2033:
2029:
2025:
2018:
2015:
2010:
2004:
2000:
1993:
1990:
1985:
1981:
1976:
1971:
1966:
1961:
1957:
1953:
1949:
1942:
1939:
1934:
1930:
1924:
1921:
1916:
1912:
1906:
1903:
1899:
1895:
1890:
1888:
1886:
1882:
1878:
1874:
1869:
1867:
1865:
1861:
1854:
1848:
1845:
1842:
1839:
1836:
1833:
1830:
1827:
1824:
1821:
1818:
1815:
1812:
1811:BLNK (SLP-65)
1809:
1807:
1804:
1803:
1801:
1799:
1791:
1789:
1787:
1783:
1775:
1768:
1764:
1763:Phase I Trial
1760:
1759:Phase I Trial
1756:
1752:
1748:
1745:
1742:
1738:
1734:
1730:
1727:
1724:
1721:
1718:
1714:
1711:
1710:
1708:
1703:
1699:
1696:
1693:
1692:
1690:
1685:
1682:
1679:
1676:
1673:
1670:
1667:
1663:
1660:
1659:
1657:
1656:
1655:
1649:
1645:
1641:
1637:
1636:Orelabrutinib
1634:
1631:
1630:Pirtobrutinib
1628:
1625:
1622:
1619:
1615:
1612:
1609:
1605:
1601:
1600:Acalabrutinib
1598:
1595:
1592:
1591:
1590:
1584:
1582:
1580:
1576:
1572:
1568:
1564:
1556:
1554:
1552:
1548:
1544:
1536:
1532:
1527:
1525:
1522:
1518:
1514:
1505:
1498:
1496:
1490:
1486:
1484:
1480:
1476:
1472:
1464:
1462:
1461:development.
1460:
1456:
1453:
1449:
1445:
1441:
1437:
1434:(abbreviated
1433:
1421:
1416:
1412:
1408:
1405:
1401:
1394:
1392:
1389:
1385:
1381:
1377:
1374:
1370:
1366:
1359:
1357:
1351:
1347:
1344:
1338:
1336:
1332:
1328:
1322:
1318:
1315:
1311:
1304:
1302:
1296:
1292:
1289:
1283:
1281:
1277:
1273:
1267:
1263:
1260:
1258:RefSeq (mRNA)
1256:
1249:
1248:
1243:
1239:
1236:
1230:
1229:
1224:
1220:
1217:
1215:
1211:
1204:
1203:
1198:
1194:
1191:
1185:
1184:
1179:
1175:
1172:
1170:
1166:
1159:
1158:
1153:
1149:
1146:
1140:
1139:
1134:
1130:
1127:
1125:
1121:
1118:
1115:
1113:
1110:
1106:
1103:
1099:
1095:
1088:
1084:
1079:
1073:
1070:
1068:
1065:
1063:
1060:
1058:
1055:
1053:
1050:
1048:
1045:
1043:
1040:
1038:
1035:
1033:
1030:
1028:
1025:
1023:
1020:
1018:
1015:
1013:
1010:
1008:
1005:
1003:
1000:
998:
995:
993:
990:
988:
985:
983:
980:
978:
975:
973:
970:
968:
965:
963:
960:
958:
955:
953:
950:
948:
945:
943:
940:
938:
935:
933:
930:
928:
925:
923:
920:
918:
915:
913:
910:
908:
905:
903:
900:
898:
895:
893:
890:
888:
885:
883:
880:
879:
877:
874:
873:
867:
864:
862:
859:
857:
854:
852:
849:
847:
844:
842:
839:
837:
836:membrane raft
834:
832:
829:
827:
824:
822:
819:
818:
816:
813:
812:
806:
803:
801:
798:
796:
793:
791:
788:
786:
783:
781:
778:
776:
773:
771:
768:
766:
763:
761:
758:
756:
755:lipid binding
753:
751:
748:
746:
743:
742:
740:
737:
736:
733:
732:Gene ontology
729:
725:
713:
708:
704:
699:
696:
694:
690:
682:
677:
666:
662:
658:
654:
650:
646:
642:
638:
634:
630:
629:
626:
622:
617:
614:
604:
600:
596:
592:
588:
584:
580:
576:
572:
568:
567:
564:
560:
555:
552:
551:
548:
546:
542:
540:
539:
535:
534:
531:
529:
525:
521:
517:
513:
505:
500:
496:
492:
487:
477:
473:
466:
459:
453:
446:
438:
434:
430:
425:
421:
416:
412:
404:
399:
395:
391:
386:
376:
372:
365:
358:
352:
345:
341:
335:
331:
327:
322:
318:
313:
309:
305:
301:
297:
293:
289:
285:
281:
277:
273:
269:
261:
256:
249:
244:
239:
228:
226:
222:
218:
214:
210:
206:
202:
198:
194:
190:
186:
182:
178:
174:
170:
166:
162:
158:
154:
150:
146:
142:
138:
134:
130:
126:
122:
118:
114:
110:
106:
102:
98:
94:
90:
86:
82:
78:
72:
67:
64:
63:
59:
56:
49:
45:
40:
36:
32:
27:
22:
19:
5152:Translocases
5149:
5136:
5123:
5110:
5097:
5087:Transferases
5084:
5071:
4928:Binding site
4824:
4774:SRC-B family
4743:SRC-A family
4500:RET receptor
4471:AXL receptor
4393:RYK receptor
4350:DDR receptor
4326:ROR receptor
4302:TIE receptor
4278:LTK receptor
4189:EPH receptor
4156:Trk receptor
4132:HGF receptor
4069:FGF receptor
3875:
3860:
3845:
3830:
3815:
3800:
3785:
3770:
3710:
3690:
3684:
3639:(1): 67–76.
3636:
3632:
3599:
3595:
3568:
3564:
3543:
3539:
3506:
3502:
3477:
3473:
3448:
3444:
3388:
3384:
3374:
3349:
3345:
3338:
3305:
3302:FEBS Letters
3301:
3295:
3268:
3264:
3254:
3209:
3205:
3195:
3160:
3156:
3146:
3119:
3115:
3105:
3060:
3056:
3046:
3019:
3015:
3005:
2972:
2968:
2961:
2929:(1): 51–63.
2926:
2922:
2887:(1): 42–53.
2884:
2880:
2874:
2839:
2835:
2825:
2816:
2806:
2793:
2788:
2776:. Retrieved
2772:the original
2762:
2748:
2743:
2731:. Retrieved
2728:www.gene.com
2727:
2718:
2704:
2699:
2685:
2680:
2668:. Retrieved
2665:www.gene.com
2664:
2655:
2647:BioNews, Inc
2646:
2636:
2623:
2618:
2591:
2587:
2577:
2563:
2558:
2545:
2540:
2513:
2509:
2499:
2462:
2458:
2448:
2431:
2427:
2421:
2388:
2384:
2378:
2360:
2327:
2323:
2317:
2305:. Retrieved
2291:
2280:
2268:. Retrieved
2259:
2250:
2239:
2230:
2190:(1): 18577.
2187:
2183:
2173:
2121:
2117:
2107:
2072:
2068:
2058:
2031:
2027:
2017:
1998:
1992:
1955:
1951:
1941:
1932:
1923:
1914:
1905:
1795:
1792:Interactions
1786:Ogden Bruton
1779:
1713:Tirabrutinib
1684:Fenebrutinib
1678:Remibrutinib
1672:Tolebrutinib
1653:
1624:Tirabrutinib
1614:Zanubrutinib
1588:
1575:X chromosome
1560:
1528:
1510:
1494:
1468:
1451:
1443:
1439:
1435:
1431:
1430:
1353:
1335:NP_001274274
1331:NP_001274273
1324:
1298:
1280:NM_001287344
1272:NM_001287345
1269:
1245:
1226:
1200:
1181:
1155:
1136:
1116:
1111:
543:
536:
502:133,484,319
489:133,443,085
401:101,390,796
388:101,349,338
263:External IDs
74:
18:
4923:Active site
3753:PDB gallery
2795:NCT01351935
2750:NCT01659255
2706:NCT03978520
2687:NCT04544449
2625:NCT04742400
2565:NCT04032171
2547:NCT02975349
2270:15 November
1723:Spebrutinib
1662:Evobrutinib
1571:bone marrow
795:ATP binding
655:bone marrow
631:granulocyte
573:granulocyte
241:Identifiers
5195:Categories
5126:Isomerases
5100:Hydrolases
4967:Regulation
2733:10 October
2594:(1): 3–5.
2465:(1): 138.
2307:26 January
2075:: 100061.
1900:, May 2017
1879:, May 2017
1855:References
1747:Luxeptinib
1743:as of 2015
1642:(MCL) and
1549:(IP3) and
601:right lung
585:lymph node
547:(ortholog)
284:HomoloGene
5005:EC number
3531:218878743
2413:232116910
2352:218531327
1958:(1): 57.
1780:Bruton's
1776:Discovery
1709:Phase 1:
1691:Phase 2:
1658:Phase 3:
1594:Ibrutinib
1579:mutations
1517:mast cell
1465:Structure
1356:NP_038510
1327:NP_000052
1301:NM_013482
1276:NM_000061
1102:Orthologs
821:cytoplasm
292:GeneCards
5029:Kinetics
4953:Cofactor
4916:Activity
3653:16300960
3624:41318916
3616:15046600
3587:14614850
3565:Immunity
3552:12001708
3523:11913944
3425:10339589
3330:86153017
3322:10561498
3287:10981967
3265:Immunity
3187:10373551
3138:14623887
3038:11751885
2997:21014231
2989:10498607
2953:12093870
2901:15203319
2866:35499387
2778:22 March
2610:33432223
2532:31075187
2491:36183125
2405:33676628
2344:32382949
2222:31819097
2150:30619340
2124:: 2984.
2099:35128378
2050:10586892
1984:29455639
1896:–
1875:–
1798:interact
1695:ABBV-105
1618:by mouth
1565:disease
1524:receptor
1499:Function
1404:Wikidata
1081:Sources:
831:membrane
593:appendix
569:monocyte
5185:Biology
5139:Ligases
4909:Enzymes
3930:2.7.10)
3717:PDBe-KB
3707:UniProt
3494:9751072
3465:7907259
3393:Bibcode
3366:9571151
3246:9012831
3214:Bibcode
3097:9770463
3065:Bibcode
2944:2194016
2857:9256809
2482:9526392
2368:. U.S.
2299:. U.S.
2213:6901466
2192:Bibcode
2141:6305442
2090:8803661
1975:5817726
1898:Ensembl
1877:Ensembl
1729:HM71224
1446:, is a
1214:UniProt
1169:Ensembl
1108:Species
1087:QuickGO
851:cytosol
826:nucleus
522:pattern
248:Aliases
5171:Portal
5113:Lyases
4847:family
4808:family
4712:family
4683:family
4659:family
4635:family
4611:family
4587:family
4563:family
4502:family
4473:family
4461:AATYK2
4449:family
4414:family
4395:family
4376:family
4352:family
4328:family
4304:family
4280:family
4191:family
4158:family
4134:family
4122:VEGFR3
4117:VEGFR2
4112:VEGFR1
4105:family
4071:family
4058:PDGFRB
4053:PDGFRA
3999:family
3712:Q06187
3682:Human
3679:(MeSH)
3651:
3622:
3614:
3585:
3550:
3529:
3521:
3492:
3463:
3423:
3413:
3364:
3328:
3320:
3285:
3244:
3234:
3185:
3175:
3136:
3095:
3085:
3036:
2995:
2987:
2951:
2941:
2899:
2864:
2854:
2670:5 June
2608:
2530:
2489:
2479:
2411:
2403:
2385:Lancet
2350:
2342:
2220:
2210:
2148:
2138:
2097:
2087:
2048:
2028:Nature
2005:
1982:
1972:
1847:SH3BP5
1843:, and
1806:ARID3A
1800:with:
1753:, and
1731:, for
1715:, for
1459:B cell
1390:search
1388:PubMed
1247:P35991
1228:Q06187
1124:Entrez
693:BioGPS
663:zygote
635:spleen
577:spleen
380:Xq22.1
272:300300
5065:Types
4859:ZAP70
4525:STYK1
4490:TYRO3
4456:AATYK
4263:EPHB6
4258:EPHB5
4253:EPHB4
4248:EPHB3
4243:EPHB2
4238:EPHB1
4233:EPHA8
4228:EPHA7
4223:EPHA6
4218:EPHA5
4213:EPHA4
4208:EPHA3
4203:EPHA2
4198:EPHA1
4175:NTRK3
4170:NTRK2
4165:NTRK1
4093:FGFR4
4088:FGFR3
4083:FGFR2
4078:FGFR1
4049:PDGFR
4034:CSF1R
4016:INSRR
4006:IGF1R
3987:ERBB4
3982:ERBB3
3977:ERBB2
3620:S2CID
3527:S2CID
3416:26883
3326:S2CID
3237:19560
3178:84330
3088:22808
2993:S2CID
2969:Blood
2428:Drugs
2409:S2CID
2348:S2CID
2324:Drugs
2264:(FDA)
2260:U.S.
1841:PRKD1
1835:PLCG2
1829:GTF2I
1741:Lilly
1157:12229
1117:Mouse
1112:Human
1083:Amigo
651:blood
589:blood
545:Mouse
538:Human
485:Start
420:Mouse
384:Start
317:Human
288:30953
280:88216
5157:list
5150:EC7
5144:list
5137:EC6
5131:list
5124:EC5
5118:list
5111:EC4
5105:list
5098:EC3
5092:list
5085:EC2
5079:list
5072:EC1
4765:YES1
4734:TYK2
4729:JAK3
4724:JAK2
4719:JAK1
4700:SRMS
4647:PYK2
4623:MATK
4599:TNK1
4594:ACK1
4570:ABL1
4437:ROS1
4421:MUSK
4383:PTK7
4364:DDR2
4359:DDR1
4340:ROR2
4335:ROR1
4268:EPHX
4039:FLT3
4011:INSR
3972:EGFR
3876:2ge9
3861:1qly
3846:1k2p
3831:1bwn
3816:1btk
3801:1b55
3786:1awx
3771:1aww
3705:for
3649:PMID
3612:PMID
3583:PMID
3548:PMID
3519:PMID
3490:PMID
3461:PMID
3421:PMID
3362:PMID
3318:PMID
3283:PMID
3242:PMID
3183:PMID
3134:PMID
3093:PMID
3034:PMID
2985:PMID
2949:PMID
2897:PMID
2862:PMID
2780:2016
2735:2020
2672:2023
2606:PMID
2528:PMID
2487:PMID
2401:PMID
2340:PMID
2309:2023
2272:2019
2218:PMID
2146:PMID
2095:PMID
2046:PMID
2003:ISBN
1980:PMID
1823:GNAQ
1817:CAV1
1767:FLT3
1739:and
1664:for
1541:, a
1477:and
1455:gene
528:Bgee
476:Band
437:Chr.
375:Band
334:Chr.
268:OMIM
225:5FBO
221:4RX5
217:5FBN
213:5BQ0
209:5BPY
205:4ZLZ
201:4ZLY
197:4Z3V
193:4YHF
189:4RG0
185:4RFZ
181:4RFY
177:4OTR
173:4OTQ
169:4OTF
165:4OT6
161:4OT5
157:4NWM
153:3PJ3
149:3PJ2
145:3PJ1
141:3PIZ
137:3PIY
133:3PIX
129:3P08
125:3OCT
121:3OCS
117:3K54
113:3GEN
109:2Z0P
105:2GE9
101:1QLY
97:1K2P
93:1BWN
89:1BTK
85:1B55
81:1AWX
77:1AWW
58:RCSB
55:PDBe
4854:SYK
4845:SYK
4835:TXK
4830:ITK
4825:BTK
4820:BMX
4815:TEC
4806:TEC
4796:LYN
4791:LCK
4786:HCK
4781:BLK
4760:FYN
4755:FGR
4750:SRC
4710:JAK
4695:BRK
4690:FRK
4681:FRK
4671:FER
4666:FES
4657:FES
4642:FAK
4633:FAK
4618:CSK
4609:CSK
4585:ACK
4575:ARG
4561:ABL
4509:RET
4485:MER
4480:AXL
4402:RYK
4316:TEK
4311:TIE
4292:ALK
4287:LTK
4146:RON
4141:MET
4044:KIT
3703:PDB
3691:BTK
3685:BTK
3641:doi
3604:doi
3573:doi
3511:doi
3482:doi
3453:doi
3411:PMC
3401:doi
3354:doi
3350:245
3310:doi
3306:461
3273:doi
3232:PMC
3222:doi
3173:PMC
3165:doi
3124:doi
3120:279
3083:PMC
3073:doi
3024:doi
3020:277
2977:doi
2939:PMC
2931:doi
2927:196
2889:doi
2885:228
2852:PMC
2844:doi
2596:doi
2518:doi
2514:380
2477:PMC
2467:doi
2436:doi
2393:doi
2389:397
2332:doi
2208:PMC
2200:doi
2136:PMC
2126:doi
2085:PMC
2077:doi
2036:doi
2032:402
1970:PMC
1960:doi
1521:IgE
1479:SH3
1475:SH2
1452:BTK
1440:BTK
1438:or
1436:Btk
1138:695
498:End
397:End
300:OMA
296:BTK
276:MGI
255:BTK
48:PDB
24:BTK
5197::
3928:EC
3922::
3709::
3647:.
3637:18
3635:.
3618:.
3610:.
3600:32
3598:.
3581:.
3569:19
3567:.
3563:.
3542:.
3525:.
3517:.
3507:20
3505:.
3488:.
3478:56
3476:.
3459:.
3447:.
3419:.
3409:.
3399:.
3389:96
3387:.
3383:.
3360:.
3348:.
3324:.
3316:.
3304:.
3281:.
3269:13
3267:.
3263:.
3240:.
3230:.
3220:.
3210:94
3208:.
3204:.
3181:.
3171:.
3161:19
3159:.
3155:.
3132:.
3118:.
3114:.
3091:.
3081:.
3071:.
3061:95
3059:.
3055:.
3032:.
3018:.
3014:.
2991:.
2983:.
2973:94
2971:.
2947:.
2937:.
2925:.
2921:.
2909:^
2895:.
2883:.
2860:.
2850:.
2840:21
2838:.
2834:.
2815:.
2726:.
2663:.
2645:.
2604:.
2592:39
2590:.
2586:.
2526:.
2512:.
2508:.
2485:.
2475:.
2463:15
2461:.
2457:.
2432:81
2430:.
2407:.
2399:.
2387:.
2346:.
2338:.
2328:80
2326:.
2258:.
2238:.
2216:.
2206:.
2198:.
2186:.
2182:.
2158:^
2144:.
2134:.
2120:.
2116:.
2093:.
2083:.
2071:.
2067:.
2044:.
2030:.
2026:.
1978:.
1968:.
1956:17
1954:.
1950:.
1931:.
1913:.
1884:^
1863:^
1761:;
1526:.
1085:/
504:bp
491:bp
403:bp
390:bp
298:;
294::
290:;
286::
282:;
278::
274:;
270::
223:,
219:,
215:,
211:,
207:,
203:,
199:,
195:,
191:,
187:,
183:,
179:,
175:,
171:,
167:,
163:,
159:,
155:,
151:,
147:,
143:,
139:,
135:,
131:,
127:,
123:,
119:,
115:,
111:,
107:,
103:,
99:,
95:,
91:,
87:,
83:,
79:,
5173::
5159:)
5155:(
5146:)
5142:(
5133:)
5129:(
5120:)
5116:(
5107:)
5103:(
5094:)
5090:(
5081:)
5077:(
4901:e
4894:t
4887:v
4060:)
4051:(
3926:(
3912:e
3905:t
3898:v
3746:e
3739:t
3732:v
3719:.
3698:.
3655:.
3643::
3626:.
3606::
3589:.
3575::
3554:.
3544:4
3533:.
3513::
3496:.
3484::
3467:.
3455::
3449:5
3427:.
3403::
3395::
3368:.
3356::
3332:.
3312::
3289:.
3275::
3248:.
3224::
3216::
3189:.
3167::
3140:.
3126::
3099:.
3075::
3067::
3040:.
3026::
2999:.
2979::
2955:.
2933::
2903:.
2891::
2868:.
2846::
2819:.
2782:.
2737:.
2674:.
2649:.
2612:.
2598::
2534:.
2520::
2493:.
2469::
2442:.
2438::
2415:.
2395::
2354:.
2334::
2311:.
2274:.
2224:.
2202::
2194::
2188:9
2152:.
2128::
2122:9
2101:.
2079::
2073:6
2052:.
2038::
2011:.
1986:.
1962::
1935:.
1917:.
1849:.
1837:,
1831:,
1825:,
1819:,
1813:,
1769:.
1757:(
1704:.
1668:.
1646:/
1620:.
1539:2
422:)
319:)
302::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
